Amsterdam EA, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2014;64(24):2645–87.

Article  Google Scholar 

Husted S, van Giezen JJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27(4):259–74.

Article  CAS  PubMed  Google Scholar 

Li Y, Landqvist C, Grimm SW. Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets. Drug Metab Dispos. 2011;39(9):1555–67.

Article  CAS  PubMed  Google Scholar 

Storey RF. Pharmacology and clinical trials of reversibly-binding P2Y12 inhibitors. Thromb Haemost. 2011;105(Suppl 1):S75–81.

CAS  PubMed  Google Scholar 

Teng R. Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: an update. Clin Pharmacokinet. 2015;54(11):1125–38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sandinge AS, et al. Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452. PLoS ONE. 2018;13(7):e0201202.

Article  PubMed  PubMed Central  Google Scholar 

Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52(9):1388–98.

Article  CAS  PubMed  Google Scholar 

Jeong KH, et al. Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with Kidney Failure treated with hemodialysis: a randomized crossover study. Am J Kidney Dis. 2015;65(6):916–24.

Article  CAS  PubMed  Google Scholar 

Teng R, Butler K. Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers. J Drug Assess. 2013;2(1):30–9.

Article  PubMed  PubMed Central  Google Scholar 

Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73(15):1681–709.

Kuczyńska K, Boncler M. Emerging role of Fentanyl in Antiplatelet Therapy. J Cardiovasc Pharmacol. 2020;76(3):267–75.

PubMed  Google Scholar 

Franchi F, et al. Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet effects in Coronary Artery Disease patients treated with Morphine. JACC: Cardiovasc Interventions. 2019;12(16):1538–49.

Google Scholar 

Iglesias JF, Valgimigli M, Carbone F, Lauriers N, Masci PG, Degrauwe S. Comparative effects of fentanyl versus morphine on platelet inhibition induced by ticagrelor in patients with ST-segment elevation myocardial infarction: full results of the PERSEUS randomized trial. Cardiol J. 2022;29(4):591–600.

Gurbel PA, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery Disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85.

Article  CAS  PubMed  Google Scholar 

JJ VANG, et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7(9):1556–65.

Article  Google Scholar 

Aungraheeta R, et al. Inverse agonism at the P2Y12 receptor and ENT1 transporter blockade contribute to platelet inhibition by ticagrelor. Blood. 2016;128(23):2717–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Astrand M, et al. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery Disease and prior Myocardial Infarction patients. Br J Clin Pharmacol. 2019;85(2):413–21.

Article  PubMed  Google Scholar 

Venetsanos D, et al. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res. 2017;149:88–94.

Article  CAS  PubMed  Google Scholar 

Marian MJ, et al. Effects of Crushed Ticagrelor Versus Eptifibatide Bolus Plus Clopidogrel in Troponin-negative Acute Coronary Syndrome patients undergoing percutaneous coronary intervention: a Randomized Clinical Trial. J Am Heart Assoc. 2019;8(23):e012844.

Article  PubMed  PubMed Central  Google Scholar 

Franchi F, et al. Platelet inhibition with Cangrelor and Crushed Ticagrelor in patients with ST-Segment-Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention. Circulation. 2019;139(14):1661–70.

Article  CAS  PubMed  Google Scholar 

Hochholzer W, Neumann FJ. [The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation] Dtsch Med Wochenschr, 2016. 141(11): p. 782-5.

Anderson JL et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol, 2013. 61(23): p. e179-347.

Franchi F, et al. Impact of escalating loading dose regimens of Ticagrelor in patients with ST-Segment Elevation Myocardial Infarction undergoing primary percutaneous coronary intervention: results of a prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation. Volume 8. JACC: Cardiovascular Interventions; 2015. pp. 1457–67. 11.

Wallentin L, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.

Article  CAS  PubMed  Google Scholar 

Wang Q, Lin W. Application of ticagrelor in the treatment of acute coronary syndrome. Shandong Med. 2015;55(7):77–9.

CAS  Google Scholar 

Liu HL, et al. Design and rationale of the APELOT Trial: a randomized, Open-Label, Multicenter, Phase IV Study to evaluate the Antiplatelet Effect of different loading dose of Ticagrelor in patients with Non-ST Acute Coronary Syndrome undergoing percutaneous coronary intervention. Med (Baltim). 2016;95(22):e3756.

Article  CAS  Google Scholar 

James S, et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the platelet inhibition and patient outcomes (PLATO) trial. Circulation. 2010;122(11):1056–67.

Article  PubMed  Google Scholar 

Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–93.

Article  CAS  PubMed  Google Scholar 

Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass Surgery: results from the PLATO (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol. 2011;57(6):672–84.

Article  CAS  PubMed  Google Scholar 

Gurbel PA, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–99.

Article  CAS  PubMed  Google Scholar 

Biswas M, Kali SK. Association of CYP2C19 loss-of-function alleles with major adverse Cardiovascular events of Clopidogrel in stable coronary artery Disease patients undergoing percutaneous coronary intervention: Meta-analysis. Cardiovasc Drugs Ther. 2021;35(6):1147–59.

Article  CAS  PubMed  Google Scholar 

Biswas M, et al. Risk of major adverse cardiovascular events of CYP2C19 loss-of-function genotype guided prasugrel/ticagrelor vs clopidogrel therapy for acute coronary syndrome patients undergoing percutaneous coronary intervention: a meta-analysis. Platelets. 2021;32(5):591–600.

Article  CAS  PubMed  Google Scholar 

Stimpfle F, et al. Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting. Thromb Res. 2014;134(1):105–10.

Article  CAS  PubMed  Google Scholar 

Biswas M, et al. Effects of the ABCB1 C3435T single nucleotide polymorphism on major adverse cardiovascular events in acute coronary syndrome or coronary artery Disease patients undergoing percutaneous coronary intervention and treated with clopidogrel: a systematic review and meta-analysis. Expert Opin Drug Saf. 2020;19(12):1605–16.

Article  CAS  PubMed  Google Scholar 

Holmberg MT, et al. CYP3A4*22 impairs the elimination of Ticagrelor, but has no significant effect on the Bioactivation of Clopidogrel or Prasugrel. Volume 105. Clinical Pharmacology & Therapeutics; 2019. pp. 448–57. 2.

Liu S, et al. Effect of CYP3A4(*)1G and CYP3A5(*)3 polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in healthy Chinese subjects. Front Pharmacol. 2017;8:176.

PubMed  PubMed Central  Google Scholar 

Badrnya S, et al. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein. Thromb Haemost. 2012;108(4):719–29.

Article  CAS  PubMed  Google Scholar 

Webster CM, et al. Microglial P2Y12 deficiency/inhibition protects against brain ischemia. PLoS ONE. 2013;8(8):e70927.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu O, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic Aneurysm progression. PLoS ONE. 2012;7(12):e51707.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Solheim S, et al. No difference in the effects of clopidogrel and aspirin on inflammatory markers in patients with coronary Heart Disease. Thromb Haemost. 2006;96(5):660–4.

CAS  PubMed  Google Scholar 

Chen YG, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J (Engl). 2006;119(1):32–6.

Article  CAS  PubMed  Google Scholar 

Liu S, et al. Effect of CYP3A4(∗)1G and CYP3A5(∗)3 polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in healthy Chinese subjects. Front Pharmacol. 2017;8:176.

PubMed  PubMed Central